SAN DIEGO, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has entered into an evaluation and supply agreement with GenomIdea Inc., a subsidiary of AnGes MG, Inc., for the development of a DNA vaccine for livestock against pandemic influenza. Funding for the project is provided under a grant from "The Okinawa New Industry Creation Research & Development Support Business," supported by the Okinawa Industry Promotion Public Corporation.
